RECURRENT LUNG SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to outsmart Chemo-Resistant lung cancer
Disease control OngoingThis phase 2 trial tests whether adding berzosertib to standard chemotherapy (topotecan) helps people with relapsed small-cell lung cancer live longer without their cancer growing. About 104 participants will receive either the combo or topotecan alone. The goal is to see if berz…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a PARP inhibitor boost chemo for tough lung cancer?
Disease control OngoingThis study tested whether adding veliparib (a PARP inhibitor) to the chemotherapy drug temozolomide helps people with small cell lung cancer that has come back or stopped responding to treatment. About 97 participants received either the drug combo or a placebo with temozolomide.…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New cocktail of drugs targets Tough-to-Treat lung cancer
Disease control OngoingThis early-phase trial tests a combination of three drugs—tazemetostat, topotecan, and pembrolizumab—in 18 adults with small cell lung cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combination can shrink or stabilize the canc…
Matched conditions: RECURRENT LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC